LONDON -- There are things to love and loathe about most companies. Today, I'm going to tell you about three things to loathe about�GlaxoSmithKline� (LSE: GSK ) (NYSE: GSK ) .
I'll also be asking whether these negative factors make this FTSE 100 pharmaceuticals giant a poor investment today.
Long-term returns
GSK's long-run total return for shareholders (capital appreciation and dividends over the past 10 years) has lagged behind that of the average FTSE 100 company. Furthermore, as the table below shows, GSK has been one of the poorer performers among its European big pharma peers.
over 10 years
(annualized) Roche 9.4% Novartis 8.6% Sanofi 8.3% GlaxoSmithKline 5.9% AstraZeneca 5.3%
Margin pressures
GSK, like all the established big pharma companies, faces what it calls�"intense competition"�from generic products within all of its major markets. This is particularly true of the U.S., where GSK has its highest turnover and margins, both of which are now under pressure from generics.
Best Biotech Stocks To Own Right Now: Ziggo NV (ZIGGO)
Ziggo NV is the Netherlands-based provider of entertainment, information and communication through television, Internet and telephony services. The Company provides digital, interactive and high definition (HD) television, broadband Internet, data communication and telephony services to both private and corporate customers. To business customers, it offers services over the network. For home use and small business, they are provided through business bundles and packages, such as Office Basis, Internet Plus and All-in-1. Ziggo NV serves around 3 million households, with almost 1.8 million Internet subscribers, more than 2.2 million subscribers using digital television and about 1.4 million telephony subscribers. Additionally, it operates a music streaming service, Ziggo Muziek, and a fiber optic network. The Company is wholly owned by Zesko Holding BV and has several subsidiaries, such as Zesko BV, Ziggo Bond Company Holding BV and Ziggo Bond Company BV, among others. Advisors' Opinion:- [By Sarah Jones]
Ziggo NV (ZIGGO), a Dutch cable-television operator, advanced 4.5 percent to 29.58 euros, after Vodafone confirmed it approached Kabel Deutschland. Liberty Global Inc., which owns an 18 percent stake in Ziggo, had also considered bidding for the German company, two people familiar with the matter said in April.
Top 10 Companies To Watch In Right Now: Medical Properties Trust Inc (MPW)
Medical Properties Trust, Inc., incorporated on August 27, 2003, is a self-advised real estate investment trust (REIT) focused on investing in and owning net-leased healthcare facilities. The Company conducts substantially all of its business through MPT Operating Partnership, L.P. The Company acquires and develops healthcare facilities and leases the facilities to healthcare operating companies under long-term net leases, which require the tenant to bear the costs associated with the property. The Company also makes mortgage loans to healthcare operators collateralized by their real estate assets. In addition, the Company selectively makes loans to certain of its operators through its taxable REIT subsidiaries. In September 2013, Medical Properties Trust Inc completed the acquisition of the real estate of three acute care hospitals operated by IASIS Healthcare LLC.
As of February 18, 2013, the Company's portfolio consists of 82 properties: 69 facilities (of the 74 facilities that the Company owns) are leased to 23 tenants, five are under development, and the remainder are in the form of mortgage loans to three operators. The Company's owned facilities consist of 27 general acute care hospitals, 24 long-term acute care hospitals, 15 inpatient rehabilitation hospitals, two medical office buildings, and six wellness centers. The non-owned facilities on which the Company has made mortgage loans consist of three general acute care facilities, two long-term acute care hospitals, and three inpatient rehabilitation hospitals. At December 31, 2012, no one property accounted for more than 5% of the Company's total assets.
At December 31, 2012, the Company had leases with 22 hospital operating companies, eight mortgaged loans, six under development, and one property under re-development covering 82 facilities. Ernest leased 12 of these facilities pursuant to a master lease agreement. The master lease agreement has a 20-year term with three five-year extension options and provides for ! an initial rental rate of 9%, with consumer price-indexed increases, limited to a 2% floor and 5% ceiling annually thereafter. At December 31, 2012, these facilities had an average remaining lease term of approximately 19 years. In addition to the master lease, the Company holds a mortgage loan on four facilities owned by affiliates of Ernest.
Affiliates of Prime Healthcare Services, Inc. (Prime) leased 11 facilities pursuant to master lease agreements. The master leases are for 10 years commencing July 3, 2012 and contain two renewal options of five years each. The initial lease rate is generally consistent with the blended average rate of the prior lease agreements. However, the annual escalators, which in the prior leases were limited, have been increased to reflect 100% of CPI increases, along with a 2% minimum floor. The master leases include repurchase options substantially similar to those in the prior leases, including provisions establishing minimum repurchase prices equal to the Company's total investment. In addition to leases, the Company holds mortgage loans on three facilities owned by affiliates of Prime.
Advisors' Opinion:- [By Brad Thomas]
A Bank of America (BOA) downgrade sends Medical Properties Trust (MPW) tumbling. The bank cut the shares to Underperform from Neutral citing the REIT's YTD outperformance relative to the sector overall (it has outpaced healthcare REITs two to one). Put simply, funds from operations "multiple expansion has exceeded fundamental trends." SA contributor Brad Thomas claims MPW is an example of mispriced risk.
- [By Eric Volkman]
It was an impressive quarter for Medical Properties Trust (NYSE: MPW ) . In its Q1 report, revenues amounted to $58 million, up 42% from the $41 million in the same period the previous year. Attributable net profit advanced much more strongly, growing 148% to $26 million ($0.18 per diluted share) from Q1 2012's figure of $11 million ($0.08). Funds from operations -- a key metric for real estate investment trusts -- came in at $35 million ($0.25 per diluted share) on a normalized basis, compared with $22 million ($0.18) in the year-ago quarter.
- [By Rich Duprey]
Real estate investment trust�Medical Properties Trust� (NYSE: MPW ) �announced yesterday�its second-quarter dividend of $0.20 per share, the same rate it's paid since 2008.
Top 10 Companies To Watch In Right Now: Ishares Trust Russell (IWD)
iShares Russell 1000 Value Index Fund (the Fund) seeks investment results that correspond generally to the price and yield performance of the large-capitalization value sector of the United States equity market, as represented by the Russell 1000 Value Index (the Index). The Index is a subset of the Russell 1000 Index. The Index is a capitalization-weighted index and consists of those companies or portion of a company, with lower price-to-book ratios and lower forecasted growth within the Russell 1000 Index. The Index represents approximately 51% of the total market capitalization of the Russell 1000 Index.
The Fund invests in a representative sample of securities included in the Index that collectively has an investment profile similar to Index. iShares Russell 1000 Value Index Fund's investment advisor is Barclays Global Fund Advisors.
Advisors' Opinion:- [By James Brumley]
It’s been especially untrue the last few years. Since this point in the year back in 2003, the iShares Russell 1000 Growth Fund (IWF) has advanced 81%, while the iShares Russell 1000 Value Fund (IWD) has only advanced 67%.
Top 10 Companies To Watch In Right Now: Diana Containerships Inc.(DCIX)
Diana Containerships Inc. owns and operates containerships in Greece. The company engages in the seaborne transportation of semi-finished and finished consumer and industrial products. As of February 23, 2012, its fleet consisted of 8 containerships with a carrying capacity of approximately 32,693 twenty-foot equivalent units. Diana Containerships Inc. was founded in 2010 and is based in Athens, Greece.
Advisors' Opinion:- [By Monica Gerson]
Diana Containerships (NASDAQ: DCIX) is projected to report its Q1 earnings at $0.01 per share on revenue of $13.22 million.
Intrawest Resorts Holdings (NYSE: SNOW) is expected to post its Q3 earnings at $2.69 per share on revenue of $294.89 million.
Top 10 Companies To Watch In Right Now: bluebird bio Inc (BLUE)
bluebird bio, Inc., incorporated on April 16, 1992, is a clinical-stage biotechnology company, the Company is focused on transforming the lives of patients with severe genetic and orphan diseases using gene therapy. Gene therapy seeks to introduce a functional copy of the defective gene into a patient�� own cells, a process called gene transfer. Through gene transfer, a functional copy of the mutated gene is delivered to the patient�� cells, thereby correcting the underlying genetic defect that causes aberrant gene expression. As of December 31, 2012, the Company is conducting a Phase I/II clinical study in France evaluating an earlier generation of its LentiGlobin vector for the treatment of �-thalassemia major and SCD. Initial proof-of-concept data from this study were published in Nature. During the year ended December 31, 2013, the Company plans to initiate an extension of this study under a revised protocol for LentiGlobin, which the Company refers to as the HGB-205 Study. The Company also plans o initiate a second Phase I/II clinical program in the United States for LentiGlobin, which the Company refers to as the HGB-204 Study, for �-thalassemia major. In March 2013, the Company entered into a strategic collaboration with Celgene Corporation, or Celgene, to discover, develop and commercialize, disease-altering gene therapies in oncology.
Its gene therapy platform is based on viral vectors that utilize a modified, non-replicating version of the Human Immunodeficiency Virus Type 1 (HIV-1) virus, that has been stripped of all of the components required for it to self-replicate and infect additional cells. The HIV-1 virus is part of the lentivirus family of viruses, as a result of which the Company refer to its vectors as lentiviral vectors. Its lentiviral vectors are used to introduce a functional copy of a gene to the patient�� own isolated blood stem cells, called hematopoietic stem cells (HSCs), which reside in a patient�� bone marrow and are capable of differentiating int! o a wide range of cell types. HSCs are dividing cells, thus its approach allows for sustained expression of the modified gene as the Company is able to take advantage of a lifetime of replication of the gene-modified HSCs. Additionally, the Company has developed a cell-based vector manufacturing process that is both reproducible and scalable.
Adrenoleukodystrophy
Adrenoleukodystrophy is a rare X-linked, inherited, neurological disorder that is often fatal. ALD is caused by mutations in the ABCD1 gene which encodes for a protein called the ALD protein (ALDP), which plays a critical role in the breakdown and metabolism of long-chain fatty acids (VLCFA). Without functional ALDP, VLCFA accumulate in cells including neural cells in which they cause damage to the myelin sheath, a protective and insulating membrane that surrounds nerve cells in the brain. This damage can result in decreased motor coordination and function, visual and hearing disturbances, the loss of cognitive function, dementia, seizures, adrenal dysfunction and other complications, including death. ALD is divided into various sub-segments with three main phenotypes that impact brain function: CCALD (Childhood cerebral adrenoleukodystrophy, AMN (Adrenomyeloneuropathy) and ACALD (Adult Cerebral ALD).
�-thalassemia
�-thalassemia is a rare hereditary blood disorder caused by a genetic abnormality of the �-globin gene resulting in defective red blood cells (RBCs). Genetic mutations cause the absence or reduced production of the beta chains of hemoglobin, or �-globin, thereby preventing the proper formation of hemoglobin A, which normally accounts for greater than 95% of the hemoglobin in the blood of adults. Hemoglobin is an iron-containing protein in the blood that carries oxygen from the respiratory organs to the rest of the body. Hemoglobin A consists of four chains-two chains each of a-globin and �-globin. Normally existing at an approximate 1:1 ratio, genetic mutations that impair t! he produc! tion of �-globin can lead to a relative excess of a-globin, premature death of red blood cells. The clinical implications of the a-globin/�-globin imbalance are two-fold: first, patients lack sufficient RBCs and hemoglobin to effectively transport oxygen throughout the body and can become severely anemic; and second, the shortened life span and ineffective production of RBCs can lead to other complications such as splenomegaly, marrow expansion, bone deformities, and iron overload in organs.
Sickle cell disease
Sickle cell disease (SCD) is a hereditary blood disorder resulting from a mutation in the �-globin gene that causes polymerization of hemoglobin proteins and abnormal red blood cell function. The disease is characterized by anemia, vaso-occlusive pain crisis (a common complication of SCD in which there is severe pain due to obstructed blood flow in the bones, joints, lungs, liver, spleen, kidney, eye, or central nervous system), infections, stroke, overall poor life and early death in a subset of patients. Under low-oxygen conditions, which are exacerbated by the red blood cell abnormalities, the mutant hemoglobin aggregates causing the RBCs to take on a sickle shape (sickle cells), which causes them to aggregate and obstruct small blood vessels, thereby restricting blood flow to organs resulting in pain, cell death and organ damage. If oxygen levels are restored, the hemoglobin can disaggregate and the RBCs return to their normal shape, but over time, the sickling damages the cell membrane and the cells fail to return to the normal shape even in high-oxygen conditions.
Advisors' Opinion:- [By Garrett Cook]
Bluebird Bio (NASDAQ: BLUE) shares shot up 34.74 percent to $35.15 following the presentation of positive data on LentiGlobin BB305 at the European Hematology Association (EHA).
- [By Jay Silverman]
Some of the biggest leaders in that field, and there have been dozens in fields, if not more this year, such as Bluebird (BLUE) and Stemline Therapeutics (STML) and have all pulled back to significantly lower levels; even below, in Bluebird's case, the price that had actually opened up as an IPO, even though it's above its IPO price.
- [By Garrett Cook]
Bluebird Bio (NASDAQ: BLUE) shares shot up 33.61 percent to $34.86 following the presentation of positive data on LentiGlobin BB305 at the European Hematology Association (EHA).
- [By David Williamson]
In this video, health-care analyst David Williamson takes a look at the tremendous success of the�Bluebird Bio (NASDAQ: BLUE ) �IPO. The company increased the size of its initial public offering, and priced shares at $17 -- above the top end of its range -- but that still couldn't contain investor appetite for this stock. Shares shot up 50% on the opening day of trading, and have remained there.
Top 10 Companies To Watch In Right Now: Astellas Pharma Inc (4503)
Astellas Pharma Inc. is a Japan-based company mainly engaged in the pharmaceutical business. The Company is involved in the manufacture and sale of pharmaceutical products in Japan, the United States, Europe, China, Korea and Taiwan, through its subsidiaries. Its main products include immunosuppressive drug Prograf, overactive bladder agent Vesicare, Protopic ointment for atopic dermatitis, Harnal for prostatic and urethral smooth muscle, and antimycotic agent Funguard, among others. It also provides pharmaceutical products for gastritis, osteoporosis, hypertension, schizophrenia, rheumatoid arthritis, atopic dermatitis and other diseases. As of March 31, 2014, the Company had 79 subsidiaries and six associated companies. Advisors' Opinion:- [By John Udovich]
Small cap FibroGen Inc is a research-based biotechnology company using its expertise in connective tissue growth factor (CTGF) and hypoxia-inducible factor (HIF) biology to discover, develop and commercialize novel therapeutics for serious unmet medical needs. In 2006, FibroGen Inc entered an licensing agreement with Astellas Pharma Inc (TYO: 4503) that provides Astellas development and marketing rights to roxadustat (FG-4592) and certain other FibroGen HIF prolyl hydroxylase inhibitors for the treatment of anemia in Europe, Commonwealth of Independent States (CIS), Middle East and South Africa. In 2013, FibroGen Inc entered an licensing arrangement with AstraZeneca plc (NYSE: AZN) that provides AstraZeneca development and commercialization rights to roxadustat (FG-4592) for the treatment of anemia associated with chronic kidney disease (CKD) and end-stage renal disease (ESRD). Current clinical trials include the following:
Top 10 Companies To Watch In Right Now: TE Connectivity Ltd.(TEL)
TE Connectivity Ltd. provides engineered electronic components, network solutions, specialty products, and subsea telecommunication systems. Its Electronic Components segment supplies passive electronic components, which include connectors and interconnect systems, relays, switches, sensors, and wire and cable to original equipment manufacturers and their contract manufacturers in the automotive, data communications, industrial, appliance, computer, and consumer devices markets. The company?s Network Solutions segment supplies infrastructure components and systems for telecommunications and energy markets. This segment provides components comprising connectors, above- and below-ground enclosures, heat shrink tubing, cable accessories, surge arrestors, fiber optic cabling, copper cabling, and racks for copper and fiber networks; electronic systems for test access and intelligent cross-connect applications; and integrated cabling solutions for cabling and building management . This segment also sells insulators, power measurement products, CATV accessories, network interface devices, raceway systems, and duct accessories. Its Specialty Products segment offers engineered custom solutions, components, and connectors for electronic systems, subsystems, and devices in the aerospace, defense, and marine; touch systems; medical; and circuit protection markets. The company?s Subsea Communications segment designs, builds, maintains, and tests undersea fiber optic networks for the telecommunications, and oil and gas markets. It sells its products in the Americas, Europe/the Middle East/Africa, and the Asia-Pacific. The company was formerly known as Tyco Electronics Ltd. and changed its name to TE Connectivity Ltd. on March 10, 2011. TE Connectivity Ltd. was founded in 1941 and is based in Schaffhausen, Switzerland.
Advisors' Opinion:- [By Garrett Cook]
Measurement Specialties (NASDAQ: MEAS) shares shot up 10.46 percent to $86.16 after the company agreed to be acquired by TE Connectivity (NYSE: TEL) for $86 cash per share.
- [By GURUFOCUS]
TE Connectivity Ltd. (TEL) designs and manufactures products that connect power, data, and signal automotive, energy, industrial, broadband communications, consumer devices, aerospace and defense, and health care industries. Dec. 3, the company increased its quarterly dividend 16% to $0.29 per share. The yield based on the new payout is 2.2%.
- [By alicet236]
TE Connectivity Ltd. (TEL): Chairman and CEO Thomas J. Lynch Sold 49,021 Shares
Chairman and CEO of TE Connectivity Ltd. (TEL) Thomas J. Lynch sold 49,021 shares on 10/07/2013 at an average price of $51.6. Te Connectivity Ltd. has a market cap of $21.44 billion; its shares were traded at around $51.85 with a P/E ratio of 17.20 and P/S ratio of 1.70. The dividend yield of TE Connectivity Ltd. stocks is 1.80%.
- [By Garrett Cook]
Measurement Specialties (NASDAQ: MEAS) shares shot up 10.50 percent to $86.19 after the company agreed to be acquired by TE Connectivity (NYSE: TEL) for $86 cash per share.
No comments:
Post a Comment